Yüksel Ürün: Put Patients First: Tailor to Comorbidities, Life Expectancy and Access
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared an article on X:
“ASCO 2024 mCRPC Update:
Put patients first: tailor to comorbidities, life expectancy and access
Genomic testing (BRCA1/2, HRR, MSI, TMB) = must
PARP inhibitors: for BRCA1/2, maybe others
Lu-PSMA: for PSMA+ after ARPI and chemo
No ARPI after ARPI—unless no options.”
Title: Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
Journal: Journal of Clinical Oncology
Authors: Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, R. Bryan Rumble, Mary-Ellen Taplin, Terry M. Kungel, Daniel Herchenhorn, Tian Zhang, Kathryn E. Beckermann, Neha Vapiwala, , Michael A. Carducci, Paul Celano, Sebastien J. Hotte, Arnab Basu, Hala Borno, Alan H. Bryce, Peng Wang, Elizabeth Wulff-Burchfield, Lisa Bodei, Andrew Loblaw, Hamid Emamekhoo, Thomas A. Hope, Huan He, M. Hassan Murad, Hongfang Liu, James Elbert Williams Jr, Rahul A. Parikh
Read the Full Article.
More posts featuring Yüksel Ürün.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023